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ADEP; ClpP; antibacterials; peptidomimicry; proteolysis Cyclic acyldepsipeptides (ADEPs) are a mechanistically novel class of antibacterial agents that exhibit potent activity against a broad range of Gram-positive bacterial pathogens, including several multidrug-resistant strains of Staphylococcus aureus, Enterococci, and Streptococcus pneumoniae. [1] ADEPs are characterized by a peptidolactone core to which is appended a N-acylphenylalanine side chain. [1a-b] Both the peptidolactone and the side chain of the naturally occurring ADEPs have been extensively modified, yielding analogs that exhibit outstanding efficacy in animal models of bacterial infection. [1c, 2] The cellular target of the ADEPs is ClpP, a peptidase which functions in collaboration with AAA+ (ATPases Associated with Diverse Cellular Activities) partners such as ClpX or ClpA to effect proteolysis of incompletely synthesized proteins or other proteins bearing a degron marker. [2c, 3, 4] ClpP is considered a self-compartmentalized peptidase by virtue of its quaternary structure, which is constituted by heptameric rings that are stacked face-to-face. The barrel-shaped tetradecamer has an interior chamber that is decorated with fourteen serine protease active sites. Consistent with ClpP's capacity to only degrade small peptides, access to the hydrolytic chamber is limited by narrow substrate entry pores located at both ends of the tetradecamer. [5] Accordingly, the proteolytic activity of ClpP is virtually contigent on AAA+ partners that recognize, unfold, and translocate substrates through the entry pores and into the ClpP hydrolytic chamber. [4] The quaternary structure and substrate selectivity of ClpP are significantly affected by ADEP binding. Apparently, ADEP binding to ClpP recapitulates some consequences of AAA+ partner binding, including conformational changes in the tetradecamer that are accompanied by opening of the substrate entry pores and reorganization of the catalytic residues. [4d,6] With its more accessible hydrolytic chamber, the ADEP-bound ClpP indiscriminately and lethally degrades large peptides, unstructured proteins, and nascent proteins as they emerge from the ribosome. [3, 6, 7] Structural studies have provided a wealth of information about the binding of ADEPs to ClpP and its consequences. [6] In crystal structures, ADEPs bind at the interfaces between ClpP monomers, which are also the putative docking sites of the AAA+ partners ( Figure  1A ). [6, 8] Hence, the binding of ADEPs to ClpP precludes its association with AAA+ partners. 3 Close inspection of the ADEP-ClpP binding interaction reveals that the ADEP peptidolactone binds the surface of ClpP and is significantly solvent exposed, while the exocyclic N-acylphenylalanine moiety binds in an extended channel formed between adjacent ClpP monomers. [6] The side chain of the phenylalanine residue occupies a deep hydrophobic pocket. Differences in the ways in which the peptidolactone and the Nacylphenylalanine moiety bind ClpP suggest that the latter plays a disproportionately important role in the protein-ligand interaction. Indeed, we have recently reported that the N-acylphenylalanine moiety of the ADEP is both necessary and sufficient for ClpP activation and antibacterial activity. [9] From molecular docking analyses, Li and co-workers have proposed that the ADEPs' N-acylphenylalanine moiety structurally mimics the highly conserved IGF/LGF loop motif of ClpX, an AAA+ partner of ClpP ( Figure 1B ). [6a] This motif is part of a flexible loop thought to dock into hydrophobic pockets at subunit interfaces on each ClpP heptamer. Although structures of the ClpX-ClpP complex have not been reported, genetic analyses in the IGF/LGF loop of ClpX indicate that this motif is essential for binding to ClpP. [8] The peptidomimicry proposals by Li et al. are quite intriguing, but lack experimental evidence. We reasoned that if the N-acylphenylalanine moiety does indeed mimic the IGF/LGF loop motif, then an ADEP analog with a dipeptide (either N-acetyl Gly-Leu or Nacetyl Gly-Ile) in place of the heptenoyl group would have equal or greater biological activity than the parent compound. Validation of this hypothesis would provide a basis for the structure-based optimization of ADEPs and design of related ClpP activators. We chose compound 1, a potent and conveniently prepared synthetic ADEP, as a point of comparison for the proposed structural modifications. [10] We envisioned replacing the N-terminal E-2heptenoyl acyl group with groups that have varying degrees of the IGF/LGF motif's peptide character (Scheme 1). First, difluorophenylalanyl peptidolactone 2 was acylated with either N-acetyl-Leu-Gly-OH or N-acetyl-Ile-Gly-OH. The resulting ADEPs (3a, 3b) represent analogs with maximal peptide character in the side chains. Next, we acylated 2 with either 5methylvaleryl-Gly-OH or 4-methylvaleryl-Gly-OH. These ADEP analogs (4a, 4b) have less peptide character in their side chains; they have termini that resemble leucine (4a) and isoleucine (4b) with the exception of the α-amino groups. Finally, we acylated 2 with α,βunsaturated carboxylic acids having methyl branches. The corresponding ADEP analogs (5a-c) possess minimal peptide character in their side chains. We purposefully selected acyl moieties with methyl substituents that were positionally analogous to those in the side chains of leucine (5a, 5b) and isoleucine (5c). We do note that the 5b and 5c have one less methylene than the IGF/LGF tripeptides.
The compounds were tested for antibacterial activity against B. subtilis, a non-pathogenic Gram-positive bacterium. Additionally, we used a ClpP activation assay to measure apparent binding constants for each ADEP analog to the B. subtilis ClpP (Figure 2 ). Intriguingly, neither 3a-b nor 4a-b exhibited any appreciable antibacterial activity. We were surprised to observe this inverse correlation between the degree of peptide character in the side chain and the bioactivity of the ADEP. Nevertheless, 3a-b and 4a-b did activate ClpP in vitro, albeit at much higher concentrations than the parent ADEP (1). In contrast, compounds 5a-c all exhibited outstanding antibacterial activity and ClpP activation in vitro. In fact, compound 5c (MIC = 0.008 μg/mL, K app = 5.1±0.1 nM) is a two-fold more potent antibacterial agent and a notably tighter ClpP binder than the unbranched compound 1 (MIC = 0.016 μg/mL, Kapp 8.3±0.1 nM). All of the active ADEPs (1, 5a-c 
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Author Manuscript ranging from 1.72 to 2.4, indicating a slight cooperativity in ClpP binding. The relatively high bioactivity of compound 5c in antibacterial and ClpP activation assays indicated that anteiso methyl branching (isoleucine-like) of the acyl moiety is advantageous. Presumably, by virtue of its position in the chain, the methyl group reduces the conformational flexibility of the acyl moiety in a manner that reduces the entropic costs of ClpP binding. Specifically, the steric bulk of the methyl group further limits rotation about the Cγ-Cδ bond, which is already constrained by allylic strain.
The improved activity of compound 5c relative to compound 1 prompted us to synthesize fully optimized ADEPs that combined our most potent conformationally constrained peptidolactone 10 with carbon branched acyl chains. In the same manner as compounds 5ac were synthesized, a straight chain and two different methyl-branched carboxylic acids were coupled to a difluorophenylalanine-functionalized peptidolactone containing conformationally constrained 4-methylpipecolate and allo-threonine residues. [10] These optimized ADEPs were tested for ClpP activation in vitro and for antibacterial activity against B. subtilis, S. aureus, S. pneumoniae, and E. faecalis (Figure 3) . Unexpectedly, the methyl branching on the acyl group did not improve the antibacterial activity of an ADEP with a conformationally constrained peptidolactone. Compounds 6a-c all exhibited similar ClpP binding in vitro and antibacterial activity in assays with B. subtilis. Nevertheless, the activities of optimized compounds 6a-c against S. pneumoniae and E. faecalis were extraordinary, with MIC ≤ 0.00002 μg/mL. Apparently, the substituents that restrict the conformation of the macrocycle have a greater effect on bioactivity than those that limit rotational freedom of the ADEPs' acyclic side chain.
Structural studies of the ADEP-ClpP binding interaction led to the proposal that the Nacylphenylalanine moiety of the ADEPs mimics the IGF/LGF loop motifs of the AAA+ partners of ClpP like ClpX. [6a] By extension, an ADEP to which is appended an IGF or LGF tripeptide would retain bioactivity or be more potent than one with N-acylphenylalanine. In this study, we found that ADEP analogs bearing exocyclic tripeptides or dipeptides analogous to the IGF and LGF motifs were weakly active in ClpP activation assays and lacked antibacterial activity. In contrast, ADEP analogs possessing difluorophenylalanine Ncapped with acyl groups having methyl branching like side chains of residues in the (I/L)GF motifs were superior to the parent ADEP with respect to both ClpP activation and bioactivity. One could argue that the (I/L)GF motif mimics on the ADEP scaffold are linear and not constrained in a ClpP binding conformation enforced by the rest of the AAA+ protein. Therefore, the N-acylphenylalanine moities of the ADEPs could be considered surrogates of the IGF or LGF motifs in AAA+ partners with enhanced physicochemical properties (e.g., reduced polarity) for ClpP binding. Indeed, the ADEPs and the motifs of the AAA+ partners are the products of distinct evolutionary pressures that would influence their affinity for ClpP. The selective pressure for ADEP evolution was tight binding to ClpP and toxicity. In contrast, the IGF or LGF motifs of the AAA+ partners are products of an evolutionary pathway directed towards weak interactions with ClpP such that dissociation for either partner exchange or regulation is facile. In any case, we were intrigued to find here and in a previously published report [11] that ADEPs bearing acyl moieties with a methyl substitution pattern reminiscent of the isoleucine side chain were better ClpP activators than those with an unbranched acyl chain. Apparently, substituents that limit the conformations of either the cyclic or acyclic groups on the ADEPs can translate to improved activities in both enzymatic and antibacterial assays. [9, 10] Further exploitation of this design strategy is underway in these laboratories. Beyond their implications for the further development of ADEPs, our findings are an important addition to the large bodies of literature on peptidomimcry by small molecules and on disruption of protein-protein interactions. [12] 
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